Annexon completes enrollment in Phase 3 ARCHER II trial

Annexon (ANNX) announced complete enrollment of the Phase 3 ARCHER II trial of vonaprument for dry age-related macular degeneration with geographic atrophy, and the company remains on track to report topline data in the second half of 2026. “Achieving and surpassing our enrollment goal ahead of schedule in ARCHER II highlights the strong interest for a treatment that can help patients preserve their vision,” said Douglas Love, president and chief executive officer of Annexon. “ARCHER II is designed to confirm the protection of visual acuity and visual structures demonstrated previously in our Phase 2 trial, and we look forward to reporting topline pivotal data in the second half of 2026.”